Cognitive adverse events in patients with lung cancer treated with checkpoint inhibitor monotherapy: a propensity score-matched analysis

[1]  J. Murre,et al.  Binary classification threatens the validity of cognitive impairment detection. , 2022, Neuropsychology.

[2]  G. Landreth,et al.  CX3CR1 deficiency aggravates amyloid driven neuronal pathology and cognitive decline in Alzheimer’s disease , 2022, Molecular Neurodegeneration.

[3]  P. Ganz,et al.  Cancer-Related Cognitive Impairment in Patients With a History of Breast Cancer. , 2021, JAMA.

[4]  C. Grohé,et al.  Association Between Neuronal Autoantibodies and Cognitive Impairment in Patients With Lung Cancer. , 2021, JAMA oncology.

[5]  G. Widman,et al.  Specific B- and T-cell populations are associated with cognition in patients with epilepsy and antibody positive and negative suspected limbic encephalitis , 2020, Journal of Neurology.

[6]  J. Olson,et al.  Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  E. Sigurdsson,et al.  Chronic PD-1 Checkpoint Blockade Does Not Affect Cognition or Promote Tau Clearance in a Tauopathy Mouse Model , 2020, Frontiers in Aging Neuroscience.

[8]  G. Winocur,et al.  Cancer-Related Cognitive Impairment: An update on state of the art, detection, and management strategies in cancer survivors. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  F. Joly,et al.  Long-Term Fatigue and Cognitive Disorders in Breast Cancer Survivors , 2019, Cancers.

[10]  F. Joly,et al.  Potential impact of immunotherapy agents on cognitive function in cancer patients. , 2019, Journal of the National Cancer Institute.

[11]  F. Kiecker,et al.  Neuronal autoantibodies associated with cognitive impairment in melanoma patients , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  I. Amit,et al.  PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model , 2019, Nature Communications.

[13]  I. Amit,et al.  PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model , 2019, Nature Communications.

[14]  L. Minasian,et al.  Longitudinal Trajectory and Characterization of Cancer-Related Cognitive Impairment in a Nationwide Cohort Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Theresa A. Koleck,et al.  Exploratory Study of Associations Between DNA Repair and Oxidative Stress Gene Polymorphisms and Cognitive Problems Reported by Postmenopausal Women With and Without Breast Cancer , 2018, Biological research for nursing.

[16]  C. Ritchie,et al.  Distinct attentional function profiles in older adults receiving cancer chemotherapy. , 2018, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

[17]  T. Horowitz,et al.  A Call for a Neuroscience Approach to Cancer-Related Cognitive Impairment , 2018, Trends in Neurosciences.

[18]  Joel L. Voss,et al.  Hippocampal functional connectivity is related to self-reported cognitive concerns in breast cancer patients undergoing adjuvant therapy , 2018, NeuroImage: Clinical.

[19]  S. Cuzzubbo,et al.  Assessing cognitive function in patients treated with immune checkpoint inhibitors: A feasibility study , 2018, Psycho-oncology.

[20]  L. Pyter,et al.  Neuroimmunology of Behavioral Comorbidities Associated With Cancer and Cancer Treatments , 2018, Front. Immunol..

[21]  M. Bühner,et al.  Chemotherapy and Post-traumatic Stress in the Causation of Cognitive Dysfunction in Breast Cancer Patients , 2017, Journal of the National Cancer Institute.

[22]  C. Heckler,et al.  Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Dauchy,et al.  Prospective Evaluation of the Impact of Antiangiogenic Treatment on Cognitive Functions in Metastatic Renal Cancer. , 2016, European urology focus.

[24]  R. Frischknecht,et al.  GABAergic drug use and global, cognitive, and motor functional outcomes after stroke. , 2016, Annals of physical and rehabilitation medicine.

[25]  W. Wick,et al.  Neurological sequelae of cancer immunotherapies and targeted therapies. , 2016, The Lancet. Oncology.

[26]  Y. T. Cheung,et al.  Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: cognitive function (FACT-Cog) in breast cancer patients. , 2013, Journal of clinical epidemiology.

[27]  T. Ahles,et al.  International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. , 2011, The Lancet. Oncology.

[28]  T. Hoffmann,et al.  Occupational therapy for cognitive impairment in stroke patients. , 2010, The Cochrane database of systematic reviews.

[29]  P. Austin.  Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples , 2009, Statistics in medicine.

[30]  Jennifer C Cornman,et al.  Measuring Subjective Social Status: A Case Study of Older Taiwanese , 2007, Journal of cross-cultural gerontology.

[31]  Andrew P. Smith,et al.  SSRIs and cognitive performance in a working sample , 2005, Human psychopharmacology.

[32]  D. Eton,et al.  Combining Distribution- and Anchor-Based Approaches to Determine Minimally Important Differences , 2005, Evaluation & the health professions.

[33]  P. Bacchetti,et al.  Sample size calculations in clinical research. , 2002, Anesthesiology.

[34]  W. Conover.  Statistical Methods for Rates and Proportions , 1974 .

[35]  S. Sherman,et al.  The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. , 2013, The Journal of clinical endocrinology and metabolism.